Abstract
Migraine aura is probably caused by cortical-spreading depression. No treatment for acute and severe migraine aura has been described previously. The effect of ketamine (25 mg intranasally) was studied in 11 patients with severe, disabling auras resulting from familial hemiplegic migraine. In five patients ketamine reproducibly reduced the severity and duration of the neurologic deficits, whereas in the remaining six patients no beneficial effect was seen. Ketamine offers, for the first time, a possible treatment option for severe and prolonged aura.
MeSH terms
-
Administration, Intranasal
-
Adult
-
Calcium Channels, P-Type / drug effects
-
Calcium Channels, P-Type / physiology
-
Calcium Channels, Q-Type / drug effects
-
Calcium Channels, Q-Type / physiology
-
Epilepsy / drug therapy*
-
Epilepsy / physiopathology*
-
Excitatory Amino Acid Antagonists / administration & dosage*
-
Female
-
Humans
-
Ketamine / administration & dosage*
-
Male
-
Migraine with Aura / drug therapy*
-
Migraine with Aura / genetics
-
Migraine with Aura / physiopathology*
-
Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors
-
Receptors, N-Methyl-D-Aspartate / drug effects
-
Receptors, N-Methyl-D-Aspartate / physiology
Substances
-
Calcium Channels, P-Type
-
Calcium Channels, Q-Type
-
Excitatory Amino Acid Antagonists
-
Receptors, N-Methyl-D-Aspartate
-
Ketamine